Skip to main content
Senzime logo

Senzime — Investor Relations & Filings

Ticker · SEZI ISIN · SE0002478776 LEI · 549300JQF174JP0MM382 ST Manufacturing
Open in API
Filings indexed 216 across all filing types
Latest filing 2024-03-07 Regulatory Filings
Country SE Sweden
Listing ST SEZI

About Senzime

https://senzime.com/en

Senzime is a medical device company that develops and markets precision-based patient monitoring solutions designed to enhance patient safety. The company's primary focus is on systems for neuromuscular and respiratory monitoring during and after surgery. Its flagship product, the TetraGraph, is an algorithm-powered monitor that provides quantitative train-of-four (TOF) monitoring based on electromyography (EMG) technology. This enables clinicians to precisely manage neuromuscular blockade, reduce postoperative complications, and improve patient outcomes. Senzime's technology supports the adoption of new clinical guidelines, aiming to establish a higher standard of care in anesthesia and recovery.

Recent filings

Filing Released Lang Actions
Senzime säkrar sin hittills största USA-affär från ledande Houston-baserat sjukhussystem
Regulatory Filings Classification · 1% confidence The document is a press release dated March 7, 2024, announcing a significant commercial milestone: securing the largest US deal for Senzime's TetraGraph system with a Texas hospital system. It details the scope of the deal (over 250 systems, potential for 100,000 patients/year) and includes quotes from the CEO. Crucially, the final section mentions: "Denna information är sådan information som Senzime är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Senzime is obliged to disclose pursuant to the EU's Market Abuse Regulation) and lists an attached PDF file. This structure—a brief announcement of material, non-financial news that is legally required to be disclosed—fits best under the general category for regulatory announcements that aren't specific financial reports (like 10-K, ER, or IR). Since it is a formal regulatory disclosure of a material event, and it is short (3510 chars) and points to an attachment, it is classified as a Regulatory Filing (RNS) rather than a specific report type like ER or MDA.
2024-03-07 Swedish
Senzime wins its largest US deal to date from leading Houston based university hospital system
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "PRESS RELEASE" dated March 7, 2024, announcing a significant commercial milestone (a large US hospital deal). It details the contract size, CEO commentary, and product information. Crucially, the end of the document states: "This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation." This strongly suggests a mandatory regulatory disclosure, but it is not a standard SEC form (like 10-K, ER, or MRQ). Since it is a general announcement mandated by regulation (MAR) that doesn't fit the specific categories like Earnings Release (ER) or Capital Update (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements not covered elsewhere. The document length is short (3677 chars) and it is an announcement, not a full financial report.
2024-03-07 English
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké Q4" and contains detailed financial figures for the fourth quarter (Q4) and the full year (Januari - december 2023), including Net Sales, Operating Result, Earnings Per Share, and key operational highlights. The structure, content (financial tables, management commentary on annual performance), and the period covered (full year and Q4) strongly indicate this is a comprehensive annual financial report summary, often released alongside or shortly before the full 10-K equivalent in non-US jurisdictions. In the context of the provided definitions, this is the primary announcement of the full year's financial performance, which aligns best with the 'Annual Report' category (10-K) or potentially an 'Interim/Quarterly Report' (IR) if it were only quarterly, but since it covers the full year and is a 'Bokslutskommuniké' (Year-end/Closing Report), 10-K is the closest fit for a comprehensive annual summary, although 'ER' (Earnings Release) is also close. Given the depth of the full-year data and the title 'Bokslutskommuniké' (Year-end Report Communication), it functions as the primary annual financial disclosure. Since the document is extensive (78k chars) and provides detailed results rather than just announcing a separate report, it is classified as the report itself. In many European contexts, this type of detailed year-end communication serves the function of the 10-K. I will classify it as 10-K as it covers the full fiscal year performance comprehensively. Q4 2023
2024-02-15 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is a 'Year-end report' for Senzime AB covering the period January-December 2023. It contains comprehensive financial statements, key performance indicators, management commentary on business trends, and operational highlights. It is clearly an interim/annual financial report rather than a simple announcement or a regulatory filing, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a specific period. FY 2023
2024-02-15 English
New number of shares and votes in Senzime AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 30, 2023, announcing a change in the total number of shares and votes following recent directed share issues. This directly relates to changes in the company's capital structure (share count and share capital). This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a press release, the core subject matter is a capital structure update, making SHA more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), as it is not merely announcing the publication of a larger report.
2023-11-30 English
Förändrat antal aktier och röster i Senzime AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated November 30, 2023, titled "Förändrat antal aktier och röster i Senzime AB (publ)" (Changed number of shares and votes in Senzime AB (publ)). It explicitly states that the total number of shares has increased due to directed share issues decided in September and November 2023. This announcement details a change in the company's capital structure (share count and share capital) resulting from financing activities. This aligns directly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it announces a specific capital change event, SHA (Share Issue/Capital Change) is also a strong candidate, but CAP covers the broader financing activity context, while SHA focuses strictly on the issuance mechanics. Given the context of directed emissions (fundraising), CAP is the most appropriate fit, although SHA is very close. I will select SHA as it specifically addresses the change in the number of shares resulting from the emission.
2023-11-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.